Progen Phase III Liver Cancer Trial To Initiate In Second Half Of 2007
This article was originally published in The Pink Sheet Daily
Company announces positive Phase II results studying PI-88 in patients who have undergone surgical removal of liver cancer.
You may also be interested in...
Companies will submit sNDA as soon as possible following study halt because of “superior overall survival efficacy.”
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.